within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX11_Palovarotene;
model Palovarotene 
   extends Pharmacolibrary.Drugs.ATC.M.M09AX11;

  annotation(Documentation(
    info ="<html><body><p>Palovarotene is a selective retinoic acid receptor gamma (RARγ) agonist developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder involving heterotopic ossification. As of 2023, palovarotene is approved in some regions for FOP and used under clinical investigation in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of single and multiple doses.</p><h4>References</h4><ol><li><p>Dube, L, et al., &amp; Le Quan Sang, KH (2023). A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants. <i>European journal of drug metabolism and pharmacokinetics</i> 48(2) 141–150. DOI:<a href=&quot;https://doi.org/10.1007/s13318-023-00815-x&quot;>10.1007/s13318-023-00815-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36802022/&quot;>https://pubmed.ncbi.nlm.nih.gov/36802022</a></p></li><li><p>Marino, R, et al., &amp; Le Quan Sang, KH (2023). The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy Participants. <i>European journal of drug metabolism and pharmacokinetics</i> 48(6) 691–707. DOI:<a href=&quot;https://doi.org/10.1007/s13318-023-00856-2&quot;>10.1007/s13318-023-00856-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37804430/&quot;>https://pubmed.ncbi.nlm.nih.gov/37804430</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Palovarotene;
